In postmenopausal women with metastatic breast cancer that has progressed despite therapy with a third-generation aromatase inhibitor, the selective estrogen receptor downregulator fulvestrant (Faslodex, AstraZeneca) has definite antitumor activity. This finding is the result of a clinical trial presented at the 27th Annual San Antonio Breast Cancer Symposium. Fulvestrant is currently approved for women in whom disease has progressed following therapy with an antiestrogen.
Go to Previous Page
Go to Next Page